Health Care/Hospital
With Child Deaths Projected to Rise for the First Time in a Century, Gates Foundation and Mohamed Bin Zayed Foundation for Humanity Urge Action as World Faces Critical Turning Point
At Goalkeepers Abu Dhabi, global leaders outline a path to improve and save the lives of millions of children through lifesaving innovation and renewed investment Partners announce $1.9 billion to advance polio eradication Event held in partnership with the Mohamed bin Zayed Foundation for Huma...
2025-12-09 03:14
104
EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide
PROVIDENCE, R.I., Dec. 9, 2025 /PRNewswire/ -- EpiVax, Inc.
2025-12-09 03:11
156
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
* In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Menarini Gro...
2025-12-09 03:05
227
Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration & beyond
SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a$10 million Seed financing round. The round was invested by Qiming Venture Partn...
2025-12-08 23:00
525
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety profile with no treatment-related serious adverse e...
2025-12-08 22:22
513
ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY 2026
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ALR Technologies SG Ltd ("ALRT" or the " Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve") showing accuracy results comparative to the leading v...
2025-12-08 22:14
556
Zymedi Announces "rapaprutug" as the International Nonproprietary Name (INN) for ZMA001
INCHEON, South Korea, Dec. 8, 2025 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that the World Health Organization (WHO) has assignedrapaprutug as the International Nonproprietary Name (INN) for the company's first-in-class antibody therapy ZMA001, being developed as a treatment for pulmon...
2025-12-08 22:00
337
Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction Model
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that ...
2025-12-08 22:00
351
PT Fapon and PT Bio Farma Forge Strategic Partnership to Advance IVD Localization and Innovation in Indonesia
DONGGUAN, China, Dec. 8, 2025 /PRNewswire/ -- PT Fapon Bioindustries Indonesia (referred to as "PT Fapon") and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as "Bio Farma") officially signed a cooperation agreement at Fapon's headquarters inDongg...
2025-12-08 20:47
470
Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
* Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. * These awards across several geographies recognize the progress represented by Voranigo® for patients living with glioma. SURESNES, France, De...
2025-12-08 20:24
425
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30 titrated weekly to target dose demonstrated approximately one-half the rate of vomiting observed w...
2025-12-08 17:40
662
Qualcomm Highlights Edge AI Innovation at Qualcomm AI Program for Innovators (QAIPI) 2025 - APAC Demo Day and Sets the Stage for 2026
Showcasing transformative edge AI innovations across robotics, healthcare and smart city solutions SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Qualcomm Technologies, Inc. hosted the Qualcomm AI Program for Innovators (QAIPI) 2025 – APAC Demo Day in Seoul, where 15 shortlisted startups from J...
2025-12-08 16:28
696
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
* Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 * Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements ...
2025-12-08 15:25
438
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first sh...
2025-12-08 14:36
433
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...
2025-12-08 10:08
721
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
NANJING, China, Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation o...
2025-12-08 10:00
587
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceuticalcompany focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignanc...
2025-12-08 09:57
499
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-12-08 09:02
789
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others
TOKYO, Dec. 8, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximatelyJPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that h...
2025-12-08 09:00
597
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...
2025-12-08 08:15
648
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 310 media titles]
2025-12-04 16:00
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
Hyundai Motor Group Fosters Collaboration with Hydrogen Industry Leaders at Hydrogen Council Global CEO Summit
[Picked up by 295 media titles]
2025-12-04 15:00
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4159
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3434
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3361
Dreame Technology Recognized on Fast Company's List of Brands That Matter
2025-12-06 01:30
3070
